Cetuximab plus talazoparib treatment elicited a significantly notable response in the monolayer cultured cells in vitro and the xenograft models in vivo, supporting a synergistic effect of these two agents, and combination therapy showed more potent antitumour activity than cetuximab treatment in the cetuximab-sensitive NSCLC PDX models, which suggests a specific role of PARP-EGFR cross-talk in PDX models (Figure 5B and Table S4). This evidence concerns the gene PARP1 and non-small cell lung carcinoma.